UroGen Pharma Ltd. (NASDAQ:URGN) is one of the Stocks With Huge Catalysts on the Horizon. On June 2, UroGen Pharma Ltd.

Board-certified medical oncologist and hematologist joins physician teamHOT SPRINGS, Ark., Aug. 06, 2025 (GLOBE NEWSWIRE) -- ...

With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...

More and more providers are beginning to incorporate the new Practical Geriatric Assessment into their practices.

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic ...

Experts debate which patients with stage III dMMR colon cancer will benefit from the two treatment approaches.

A different study presented at the 2025 ASCO Annual Meeting showed that one specific diet may benefit people with colon ...

I became a doctor because I lost someone I loved. I stayed because I believe in what we do together,” writes art director ...

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

At the end of the day, if something as simple as appointment scheduling is enough to significantly prolong life for cancer patients getting immunotherapy, doctors should factor this in when planning ...